RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancerElena Élez, Rodrigo A. Toledo, Javier Ros et al.|Nature Medicine|2022Cited by 111
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancerMargherita Ambrosini, Filippo Pietrantonio, Aurélien Marabelle et al.|Annals of Oncology|2024Cited by 73